Universal cancer peptide-based therapeutic vaccine breaks tolerance against telomerase and eradicates established tumor. Dosset, M., Godet, Y., Vauchy, C., Beziaud, L., Lone, Y. C., Sedlik, C., Liard, C., Levionnois, E., Clerc, B., Sandoval, F., Daguindau, E., Wain-Hobson, S., Tartour, E., Langlade-Demoyen, P., Borg, C., & Adotevi, O. Clin Cancer Res, 18(22):6284–95, November, 2012.
Universal cancer peptide-based therapeutic vaccine breaks tolerance against telomerase and eradicates established tumor [link]Paper  abstract   bibtex   
PURPOSE: To evaluate CD4(+) helper functions and antitumor effect of promiscuous universal cancer peptides (UCP) derived from telomerase reverse transcriptase (TERT). EXPERIMENTAL DESIGN: To evaluate the widespread immunogenicity of UCPs in humans, spontaneous T-cell responses against UCPs were measured in various types of cancers using T-cell proliferation and ELISPOT assays. The humanized HLA-DRB1*0101/HLA-A*0201 transgenic mice were used to study the CD4(+) helper effects of UCPs on antitumor CTL responses. UCP-based antitumor therapeutic vaccine was evaluated using HLA-A*0201-positive B16 melanoma that express TERT. RESULTS: The presence of a high number of UCP-specific CD4(+) T cells was found in the blood of patients with various types of cancer. These UCP-specific T cells mainly produce IFN-gamma and TNF-alpha. In HLA transgenic mice, UCP vaccinations induced high avidity CD4(+) T(H)1 cells and activated dendritic cells that produced interleukin-12. UCP-based vaccination breaks self-tolerance against TERT and enhances primary and memory CTL responses. Furthermore, the use of UCP strongly improves the efficacy of therapeutic vaccination against established B16-HLA-A*0201 melanoma and promotes tumor infiltration by TERT-specific CD8(+) T cells. CONCLUSIONS: Our results showed that UCP-based vaccinations strongly stimulate antitumor immune responses and could be used to design efficient immunotherapies in multiple types of cancers.
@article{dosset_universal_2012,
	title = {Universal cancer peptide-based therapeutic vaccine breaks tolerance against telomerase and eradicates established tumor},
	volume = {18},
	issn = {1078-0432 (PRINT) 1078-0432 (LINKING)},
	shorttitle = {Universal cancer peptide-based therapeutic vaccine breaks tolerance against telomerase and eradicates established tumor},
	url = {http://www.ncbi.nlm.nih.gov/pubmed/23032748},
	abstract = {PURPOSE: To evaluate CD4(+) helper functions and antitumor effect of promiscuous universal cancer peptides (UCP) derived from telomerase reverse transcriptase (TERT). EXPERIMENTAL DESIGN: To evaluate the widespread immunogenicity of UCPs in humans, spontaneous T-cell responses against UCPs were measured in various types of cancers using T-cell proliferation and ELISPOT assays. The humanized HLA-DRB1*0101/HLA-A*0201 transgenic mice were used to study the CD4(+) helper effects of UCPs on antitumor CTL responses. UCP-based antitumor therapeutic vaccine was evaluated using HLA-A*0201-positive B16 melanoma that express TERT. RESULTS: The presence of a high number of UCP-specific CD4(+) T cells was found in the blood of patients with various types of cancer. These UCP-specific T cells mainly produce IFN-gamma and TNF-alpha. In HLA transgenic mice, UCP vaccinations induced high avidity CD4(+) T(H)1 cells and activated dendritic cells that produced interleukin-12. UCP-based vaccination breaks self-tolerance against TERT and enhances primary and memory CTL responses. Furthermore, the use of UCP strongly improves the efficacy of therapeutic vaccination against established B16-HLA-A*0201 melanoma and promotes tumor infiltration by TERT-specific CD8(+) T cells. CONCLUSIONS: Our results showed that UCP-based vaccinations strongly stimulate antitumor immune responses and could be used to design efficient immunotherapies in multiple types of cancers.},
	number = {22},
	journal = {Clin Cancer Res},
	author = {Dosset, M. and Godet, Y. and Vauchy, C. and Beziaud, L. and Lone, Y. C. and Sedlik, C. and Liard, C. and Levionnois, E. and Clerc, B. and Sandoval, F. and Daguindau, E. and Wain-Hobson, S. and Tartour, E. and Langlade-Demoyen, P. and Borg, C. and Adotevi, O.},
	month = nov,
	year = {2012},
	keywords = {Animals CD4-Positive T-Lymphocytes/immunology/physiology CD8-Positive T-Lymphocytes/immunology/physiology Cancer Vaccines/*immunology Cell Line, Cytotoxic/immunology/physiology Telomerase/*immunology Th1 Cells/immunology/physiology Xenograft Model Antitumor Assays, Experimental/immunology/*therapy Mice Mice, Immunologic Dendritic Cells/immunology Humans Melanoma, Transgenic Peptide Fragments/*immunology T-Lymphocytes/*immunology T-Lymphocytes, Tumor Cell Proliferation Cytotoxicity},
	pages = {6284--95}
}

Downloads: 0